120 related articles for article (PubMed ID: 37722985)
1. Baseline prostate health index risk category and risk category changes during active surveillance predict grade reclassification.
de la Calle CM; Jing Y; Mamawala MM; Landis P; Macura KJ; Trock BJ; Epstein JI; Sokoll LJ; Pavlovich CP
Urol Oncol; 2023 Nov; 41(11):455.e1-455.e6. PubMed ID: 37722985
[TBL] [Abstract][Full Text] [Related]
2. Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance.
Schwen ZR; Mamawala M; Tosoian JJ; Druskin SC; Ross AE; Sokoll LJ; Epstein JI; Carter HB; Gorin MA; Pavlovich CP
BJU Int; 2020 Sep; 126(3):373-378. PubMed ID: 32367635
[TBL] [Abstract][Full Text] [Related]
3. The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?
Roscigno M; Stabile A; Lughezzani G; Pepe P; Galosi AB; Naselli A; Naspro R; Nicolai M; La Croce G; Aljoulani M; Perugini G; Guazzoni G; Montorsi F; Balzarini L; Sironi S; Da Pozzo LF
Clin Genitourin Cancer; 2020 Dec; 18(6):e698-e704. PubMed ID: 32493676
[TBL] [Abstract][Full Text] [Related]
4. Unified model involving genomics, magnetic resonance imaging and prostate-specific antigen density outperforms individual co-variables at predicting biopsy upgrading in patients on active surveillance for low risk prostate cancer.
Beksac AT; Ratnani P; Dovey Z; Parekh S; Falagario U; Roshandel R; Sobotka S; Kewlani D; Davis A; Weil R; Bashorun H; Jambor I; Lewis S; Haines K; Tewari AK
Cancer Rep (Hoboken); 2022 Mar; 5(3):e1492. PubMed ID: 34931468
[TBL] [Abstract][Full Text] [Related]
5. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M
BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Apparent Diffusion Coefficient as a Predictor of Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
Huang MM; Macura KJ; Landis P; Epstein JI; Gawande R; Carter HB; Mamawala M
Urology; 2020 Apr; 138():84-90. PubMed ID: 31954166
[TBL] [Abstract][Full Text] [Related]
7. A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study.
Luiting HB; Remmers S; Boevé ER; Valdagni R; Chiu PK; Semjonow A; Berge V; Tully KH; Rannikko AS; Staerman F; Roobol MJ
Eur Urol Oncol; 2022 Dec; 5(6):651-658. PubMed ID: 35437217
[TBL] [Abstract][Full Text] [Related]
8. Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer.
Lonergan PE; Washington SL; Cowan JE; Zhao S; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
J Urol; 2020 Dec; 204(6):1216-1221. PubMed ID: 32519915
[TBL] [Abstract][Full Text] [Related]
9. Utility of PSA Density in Predicting Upgraded Gleason Score in Men on Active Surveillance With Negative MRI.
Press BH; Khajir G; Ghabili K; Leung C; Fan RE; Wang NN; Leapman MS; Sonn GA; Sprenkle PC
Urology; 2021 Sep; 155():96-100. PubMed ID: 34087311
[TBL] [Abstract][Full Text] [Related]
10. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
Hamoen EHJ; Hoeks CMA; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Bokhorst LP; Witjes JA; Rovers MM; Hulsbergen-van de Kaa CA; Barentsz JO
Eur Urol Focus; 2019 May; 5(3):407-415. PubMed ID: 29331622
[TBL] [Abstract][Full Text] [Related]
11. Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer.
Jayadevan R; Felker ER; Kwan L; Barsa DE; Zhang H; Sisk AE; Delfin M; Marks LS
JAMA Netw Open; 2019 Sep; 2(9):e1911019. PubMed ID: 31509206
[TBL] [Abstract][Full Text] [Related]
12. The role of multiparametric magnetic resonance in active surveillance of a low-risk prostate cancer cohort from clinical practice.
Chamorro Castillo L; García Morales L; Ruiz López D; Salguero Segura J; Valero Rosa J; Anglada Curado FJ; Mesa Quesada J; Blanca Pedregosa A; Carrasco Valiente J; Gómez Gómez E
Prostate; 2023 Jun; 83(8):765-772. PubMed ID: 36895160
[TBL] [Abstract][Full Text] [Related]
13. PI-RADS® Category as a Predictor of Progression to Unfavorable Risk Prostate Cancer in Men on Active Surveillance.
Wang AZ; O’Conno LP; Yerram NK; Long L; Zeng J; Mehralivand S; Harmon SA; Lebastchi AH; Ahdoot M; Gomella PT; Gurram S; Choyke PL; Merino MJ; Shih JH; Wood BJ; Turkbey B; Pinto PA
J Urol; 2020 Dec; 204(6):1229-1235. PubMed ID: 32716685
[TBL] [Abstract][Full Text] [Related]
14. The predictive value of the prostate health index vs. multiparametric magnetic resonance imaging for prostate cancer diagnosis in prostate biopsy.
Stejskal J; Adamcová V; Záleský M; Novák V; Čapoun O; Fiala V; Dolejšová O; Sedláčková H; Veselý Š; Zachoval R
World J Urol; 2021 Jun; 39(6):1889-1895. PubMed ID: 32761380
[TBL] [Abstract][Full Text] [Related]
15. Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density.
Umbehr MH; Platz EA; Peskoe SB; Bhavsar NA; Epstein JI; Landis P; Partin AW; Carter HB
BJU Int; 2014 Apr; 113(4):561-7. PubMed ID: 23746233
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Serial Multiparametric Magnetic Resonance Imaging and Subsequent Biopsy in Men with Low-risk Prostate Cancer Managed with Active Surveillance.
Hsiang W; Ghabili K; Syed JS; Holder J; Nguyen KA; Suarez-Sarmiento A; Huber S; Leapman MS; Sprenkle PC
Eur Urol Focus; 2021 Jan; 7(1):47-54. PubMed ID: 31147263
[TBL] [Abstract][Full Text] [Related]
17. Clinically Significant Prostate Cancer Detection After a Negative Prebiopsy MRI Examination: Comparison of Biparametric Versus Multiparametric MRI.
Gan JM; Kikano EG; Smith DA; Rao S; Podury R; Wang M; Durieux JC; Paspulati RM; Ponsky L; Ramaiya NH; Tirumani SH
AJR Am J Roentgenol; 2022 May; 218(5):859-866. PubMed ID: 34817189
[No Abstract] [Full Text] [Related]
18. MRI-Based Prostate-Specific Antigen Density Predicts Gleason Score Upgrade in an Active Surveillance Cohort.
Washington SL; Baskin AS; Ameli N; Nguyen HG; Westphalen AC; Shinohara K; Carroll PR
AJR Am J Roentgenol; 2020 Mar; 214(3):574-578. PubMed ID: 31913068
[No Abstract] [Full Text] [Related]
19. In-parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the prostate health index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance.
Porpiglia F; Cantiello F; De Luca S; Manfredi M; Veltri A; Russo F; Sottile A; Damiano R
BJU Int; 2016 Oct; 118(4):527-34. PubMed ID: 26350955
[TBL] [Abstract][Full Text] [Related]
20. Prostatic-specific antigen density behavior according to multiparametric magnetic resonance imaging result.
Morote J; Celma A; Diaz F; Regis L; Roche S; Mast R; Semidey ME; de Torres IM; Planas J; Trilla E
Urol Oncol; 2020 May; 38(5):410-417. PubMed ID: 32067845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]